Olmesartan Medoxomil/Levamlodipine

The main purpose of the study is to evaluate the pharmacokinetic characteristics of Olmesartan Medoxomil-Levoamlodipine Tablets (each tablet contains 20 mg of Olmesartan Medoxomil and 2.5 mg of Levoamlodipine Besylate (calculated as C20H25ClN2O5)) taken simultaneously with Olmesartan Medoxomil Tablets (trade name: Aotan, 20 mg) and Amlodipine Besylate Tablets (trade name: Norvasc, 5 mg) in healthy subjects, and to evaluate the bioequivalence of the two in the fasting and postprandial state. Secondary purpose of the study is to evaluate the safety of Olmesartan Medoxomil-Levoamlodipine Tablets (each tablet contains 20 mg of Olmesartan Medoxomil and 2.5 mg of Levoamlodipine Besylate (calculated as C20H25ClN2O5)) taken simultaneously with Olmesartan Medoxomil Tablets (trade name: Aotan, 20 mg) and Amlodipine Besylate Tablets (trade name: Norvasc, 5 mg) in healthy subjects.